Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT05141721

Public ClinicalTrials.gov record NCT05141721. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Study identification

NCT ID
NCT05141721
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Seattle Project Corporation
Industry
Enrollment
700 participants

Conditions and interventions

Interventions

  • GRT-C901 Drug
  • GRT-R902 Drug
  • Atezolizumab Drug
  • Ipilimumab Drug
  • Fluoropyrimidine plus leucovorin Drug
  • Bevacizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 11, 2022
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027
Last update posted
May 15, 2025

2022 – 2027

United States locations

U.S. sites
43
U.S. states
24
U.S. cities
39
Facility City State ZIP Site status
Banner MD Anderson Gilbert Arizona 85234
Highlands Oncology Springdale Arkansas 72762
U.S.C Norris Cancer Center, Keck School of Medicine, Division of Medical Oncology Los Angeles California 90033
University of California - Irvine (UCI) Orange California 92697
University of California Los Angeles (UCLA) Santa Monica California 90404
Rocky Mountain Cancer Centers - USOR Denver Colorado 80218
Eastern CT Hematology and Oncology Associates (ECHO) Norwich Connecticut 06360
Lynn Cancer Institute - Boca Raton Regional Hospital Boca Raton Florida 33486
University of Miami Miami Florida 33136
Miami Cancer Institute at Baptist Health South Florida (USOR site) Miami Florida 33176
Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140
Orlando Health Orlando Florida 32806
Advanced Research (Oncology & Hemotology Associates of West Broward) Tamarac Florida 33321
University of Illinois at Chicago Chicago Illinois 60607
University of Chicago Chicago Illinois 60637
Indiana University Indianapolis Indiana 46202
University of Kansas Medical Center Fairway Kansas 66205
Norton Cancer Institute Louisville Kentucky 40202
American Oncology Partners of Maryland, PA Bethesda Maryland 20817
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89119
Astera Cancer Care East Brunswick New Jersey 08816
Summit Health Florham Park New Jersey 07932
Morristown Medical Center Morristown New Jersey 07960
Rutgers New Brunswick New Jersey 08903
NYU Langone Health New York New York 10016
Columbia University Irving Medical Center New York New York 10032
New York Cancer and Blood Port Jefferson Station New York 11776
Christ Hospital Cancer Center Cincinnati Ohio 45229
Northwest Cancer Specialists DBA Compass Oncology - USOR Portland Oregon 97227
Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia Pennsylvania 19107
Allegheny General Hospital Pittsburgh Pennsylvania 15212
Prisma Health Greenville South Carolina 29615
Tennessee Oncology - Sarah Cannon Research Institute Nashville Tennessee 37203
Vanderbilt University Medical Center Nashville Tennessee 37232
Texas Oncology PA - USOR Austin Texas 78705
Texas Oncology - Dallas Sammons Dallas Texas 75246
MD Anderson Houston Texas 77030
Baylor Scott and White Temple Texas 76508
Huntsman Cancer Institute at University of Utah Salt Lake City Utah 84112
University of Virginia Charlottesville Virginia 22903
Virginia Cancer Specialists Fairfax Virginia 22031
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05141721, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 15, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05141721 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →